Yuanda Pharmaceuticals: New domestic approval for Quaprenil injection in new specifications

Far-reaching Pharmaceuticals announced that the new specification of the company's Treprostinil Injection has obtained the drug registration certificate issued by the National Medical Products Administration on September 22. It is reported that Treprostinil Injection is a medical insurance catalog product, it is the first-line drug for treating PAH in clinical practice, and it is the foundation drug in the targeted drug combination therapy regimen. It is also the only subcutaneous and intravenous administration prostacyclin drug available in China for the treatment of PAH. The specification of this product, 20ml:20mg, has been approved for market launch in March 2023.